Drug General Information
Drug ID	D0UX2V
Former ID	DNCL001650
Drug Name	BMS-817399
Indication	Rheumatoid arthritis [ICD9: 710-719, 714; ICD10:M05-M06]		Phase 2	[523564]
Company	Bristol-Myers Squibb
Structure		Download 2D MOL 3D MOL
Target and Pathway
Target(s)	C-C chemokine receptor type 1	Target Info	Modulator	[532913]
KEGG Pathway	Cytokine-cytokine receptor interaction
	Chemokine signaling pathway
NetPath Pathway	IL5 Signaling Pathway
	TCR Signaling Pathway
	IL2 Signaling Pathway
	TNFalpha Signaling Pathway
	Leptin Signaling Pathway
PANTHER Pathway	Inflammation mediated by chemokine and cytokine signaling pathway
Reactome	Chemokine receptors bind chemokines
	G alpha (i) signalling events
WikiPathways	GPCRs, Class A Rhodopsin-like
	Peptide GPCRs
	GPCR ligand binding
	GPCR downstream signaling
References
Ref 523564	ClinicalTrials.gov (NCT01404585) Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid Arthritis. U.S. National Institutes of Health.
Ref 532913	Discovery of the CCR1 antagonist, BMS-817399, for the treatment of rheumatoid arthritis. J Med Chem. 2014 Sep 25;57(18):7550-64.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.